Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CDC approves Moderna, J&J COVID-19 boosters, mixing and matching doses

10/22/2021 | 08:42am EST

Tens of millions of additional Americans will now be able to get a COVID-19 booster shot after the Centers for Disease Control and Prevention fully authorized extra doses of the vaccines produced by Moderna and Johnson & Johnson.

CDC Director Dr. Rochelle Walensky signed off on the booster shots late Thursday after an advisory committee recommended the extra doses for older and at-risk recipients of Moderna's vaccine, and everyone who received the Johnson & Johnson vaccine, produced by Janssen.

In another major step, the CDC also authorized Americans to receive booster doses in a different brand than their original jab. For example, someone who originally received the Pfizer vaccine can get a Johnson & Johnson booster.

The approval from Walensky came after the advisory panel met for several hours Thursday to weigh the extra doses and "mixing and matching" boosters.

For the Moderna booster, the CDC authorized doses six months after the second shot for people over 65 and adults who live with underlying health conditions, in a long-term care facility or work in a high-risk field.

The qualifications for the Moderna booster are the same for Pfizer's.

For the Johnson & Johnson booster, the CDC authorized extra doses for everyone who received the single-dose vaccine. Experts said at the meeting that most of the reason for this is because data have shown that the Johnson & Johnson vaccine doesn't appear to provide as much protection as the other two vaccines.

The nearly 15 million people who received the Johnson & Johnson COVID-19 vaccine in the United States can get their booster after two months.

"These recommendations are another example of our fundamental commitment to protect as many people as possible from COVID-19," Walensky said. "The evidence shows that all three COVID-19 vaccines authorized in the United States are safe -- as demonstrated by the over 400 million vaccine doses already given. And, they are all highly effective in reducing the risk of severe disease, hospitalization, and death, even in the midst of the widely circulating Delta variant."

The Moderna and Johnson & Johnson boosters are expected to be available nationwide this weekend.

As far as mixing and matching boosters, the CDC didn't recommend any particular dose to boost protection.

"Eligible individuals may choose which vaccine they receive as a booster dose," it said. "Some people may have a preference for the vaccine type that they originally received and others, may prefer to get a different booster. CDC's recommendations now allow for this type of mix and match dosing for booster shots."

"However, today's action should not distract from the critical work of ensuring that unvaccinated people take the first step and get an initial COVID-19 vaccine," the agency added. "More than 65 million Americans remain unvaccinated, leaving themselves -- and their children, families, loved ones, and communities -- vulnerable."

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source US Top News

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -0.65% 159.2 Delayed Quote.1.82%
MODERNA, INC. 20.57% 329.63 Delayed Quote.215.53%
PFIZER, INC. 6.11% 54 Delayed Quote.46.70%
All news about MODERNA, INC.
04:34aWith new Omicron case detected, UK awaits COVID booster advice
RE
11/26Vaccine companies testing efficacy against COVID-19 Omicron variant
AQ
11/26Moderna to Test Variant-Specific Vaccine Candidate
DJ
11/26Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
BU
11/26ADRs Close Lower; BioNTech Rises, Carnival Drops
DJ
11/26US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New COVID-19 Stra..
MT
11/26CLOSE UPDATE : US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New C..
MT
11/26Delta, Carnival fall; Moderna, Clorox rise
AQ
11/26Stocks tumble on new coronavirus variant fear
RE
11/26Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns
DJ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 170 M - -
Net cash 2021 12 747 M - -
P/E ratio 2021 12,5x
Yield 2021 -
Capitalization 134 B 134 B -
EV / Sales 2021 6,93x
EV / Sales 2022 5,38x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 329,63 $
Average target price 272,53 $
Spread / Average Target -17,3%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431
ALNYLAM PHARMACEUTICALS, INC.45.06%22 548